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Abstract
Purpose—Patients with portal vein thrombosis (PVT) and hepatocellular carcinoma (HCC) have
limited treatment options due to increased disease burden and diminished hepatic perfusion. 90Y-
microspheres may be better tolerated than chemoembolization in these patients. Here we review the
safety and efficacy of 90Y-microsphere use for HCC with major PVT.
Materials and Methods—A retrospective review of HCC with main (n=10) or first (n=12) branch
PVT treated with 90Y-microspheres (n=22) was conducted. CLIP scores ranged from 2 to 5 with
18% scoring 4 or greater. Response was determined 8-12 weeks following treatment using magnetic
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resonance or computed tomography and RECIST criteria. Overall survival was estimated by the
Kaplan-Meier method.
Results—32 treatments (26 glass, 6 resin) were administered to 22 patients. Common grade 1–2
toxicities included abdominal pain (38%), nausea (28%), fatigue (22%). Four post-therapy
hospitalizations occurred, all <48hrs in duration. 1 death occurred 10 days following therapy
Response data: 2 partial responses, progressive disease 42%, stable disease 50% of treatments.
Median overall survival (OS) was 7 months from time of initial 90Y-microsphere treatment. Child-
Pugh A patients had a median OS of 7.7 months; B and C = 2.7 months (p = 0.01). Median OS for
CLIP scores 2–3 was 7 months versus 1.3 months for scores 4–5 (p = 0.04).
Conclusions—90Y-microspheres are tolerated in patients with HCC and major PVT. Compared
with chemoembolization, rates of severe adverse events appear low. Radiographic response rates are
low. Median OS of 7 months is promising and warrants further study versus systemic therapy.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with an
estimated incidence of over 600,000 per year (1). Up to 40% of patients with HCC develop
portal vein thrombosis (PVT), which poses a challenging treatment dilemma (2). The prognosis
for patients with PVT in the major branches is poor (3–5), and optimal treatment strategies are
unclear. Palliative techniques such as transarterial embolization or chemoembolization are
commonly used for the treatment of advanced HCC; however, patients with PVT may run a
greater risk of hepatic decompensation following embolic therapy due to diminished portal
venous blood flow, which compensates to maintain oxygenation of the liver when the arterial
circulation is interrupted. Because of this, embolic techniques are often contraindicated in those
with major PVT, or are limited to superselective techniques in patients with segmental or
incomplete PVT (6–7). Additionally, the value of embolic therapies in the population of
patients with PVT is unproven at this time.
The use of glass or resin yttrium-90 (90Y) microspheres is a relatively recent development in
the treatment of HCC (8–9). Published evidence of efficacy and safety with the use of
microspheres in patients with HCC and PVT is limited. Yttrium-90 microspheres are smaller
in caliber than typical embolic particles, and are delivered to a specific radiation dose rather
than to stasis. Therefore they are hypothesized to exert less of an ischemic effect compared to
other methods of embolization. Lack of an embolic effect of 90Y-microspheres has been further
demonstrated by reports showing a decreased incidence of post-embolization syndrome
following transarterial administration of 90Y-microspheres compared with
chemoembolization or transarterial embolization (10–11). Because the primary therapeutic
mechanism of 90Y-microspheres is local radiation as opposed to ischemia, it has been
postulated that 90Y-microspheres may be better tolerated than traditional embolization or
chemoembolization in patients with PVT. The purpose of this study was to test this hypothesis
by retrospectively assessing 90Y-microsphere use in a cohort of patients with advanced HCC
and main or complete first branch PVT.
Here we report the results of 22 patients treated with either glass or resin 90Y-microspheres.
Though prior studies have reported use of 90Y-microspheres in HCC with PVT, the amount
of safety, efficacy and outcomes data available is limited to subgroup analyses from one phase
II trial (12–13). Our study was carried out specifically in patients with significant PVT. To that
end we have analyzed the toxicity, response, and survival of patients with HCC and PVT
receiving 90Y-microspheres.
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This retrospective review includes patients (n=22) with confirmed HCC and main or first
branch PVT. Typically at our institution, patients with HCC without PVT or with PVT of only
a secondary branch of the portal venous system are treated with chemoembolization. At the
time 90Y-microspheres became available, we decided to utilize this therapeutic option
specifically in patients who were not felt to be good candidates for chemoembolization, or
patients whose tumors had progressed after chemoembolization (specifically those who had
developed PVT in conjunction with progression of disease). Patients treated with glass spheres
were treated under an Institutional Review Board (IRB)-approved protocol that did not specify
tumor burden or portal vein status. Separate IRB approval was obtained to review the patient
records for this study without need for additional consent. All patients provided written
informed consent for treatment with 90Y-microspheres and for collection of data for research
purposes.
All patients were discussed for suitability for 90Y-microspheres by a multidisciplinary tumor
board consisting of hepatologists, transplant surgeons, interventional radiologists and a
medical oncologist. Eligibility for treatment with 90Y-microspheres was based on: age ≥ 18
years, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, confirmed
diagnosis of surgically unresectable HCC (biopsy proven or alpha-fetoprotein, AFP > 400) and
first or main branch PVT as determined by computed tomography (CT) or magnetic resonance
(MR) imaging. Pertinent criteria for patient exclusion included: pregnancy, uncontrolled
ascites, encephalopathy, and coagulopathy. Significantly abnormal pretreatment laboratory
findings (serum creatinine ≥ 2.0 mg/dL or bilirubin > 2× upper limits of normal, ULN) were
relative contraindications for treatment. All treated patients were evaluated to confirm an
acceptable risk of shunting of 90Y-microspheres to the lungs (< 30 Gy or hepatopulmonary
shunt < 20% by tagged albumin scan) and no detectable flow to other gastrointestinal organs.
Four of the 19 patients receiving glass microspheres and one of the four patients receiving resin
microspheres required embolization of aberrant gastric arteries prior to treatment in order to
allow safe delivery of the 90Y-microspheres.
Clinical and biochemical data were obtained at baseline and 1 to 4 weeks following treatment.
A 30 day follow-up period from treatment was used as the cutoff for the safety and toxicity
analysis. Toxicities occurring beyond this time point can be related to radiation-induced liver
disease (14); however only acute toxicities were evaluated in this study.
Treatment Planning and Delivery of 90Y-microspheres
All patients had an initial medical history and physical examination. The baseline treatment
planning work-up included CT or MR imaging of the liver, technetium-99m macro-aggregated
albumin (99mTc-MAA) scan, and AFP level. Selective celiac and superior mesenteric
arteriography was performed with late-phase imaging of the portal venous system to evaluate
vascular anatomy, patency of the portal vein and the direction of portal flow. Treatment
planning and administration of 90Y-microspheres were performed according to previously
published guidelines for use of glass (15) or resin (16) 90Y-microspheres. Glass microsphere
activity is selected as an intended dose in Gray (Gy) as determined by the mass of the tumor
and liver and uses MIRD phantom calculations (17–18). Resin microsphere activity is instead
planned using a combination of the patient's liver volume, tumor volume, and body surface
area (16,19).
Liver CT and MR images were reviewed with special attention to the volume of the liver,
degree and distribution of tumor infiltration and patency of the portal vein. If a patient was
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deemed a suitable candidate for 90Y-microspheres treatment based on available information,
visceral arteriography and 99mTc-MAA scanning were performed to define arterial anatomy
and evaluate the amount of lung shunt, gastrointestinal flow, and PVT. The amount of activity
required for the target dose of 90Y-microspheres was calculated Patients were considered
eligible for 90Y-microsphere treatment if the lung shunt would result in an estimated dose of
less than 30 Gy (16.5 mCi; 610.5 GBq) to the lungs, there was no observable un-correctable
gastrointestinal flow, and liver reserve and tumor vascular anatomy were judged to be suitable
for treatment. In strict aseptic conditions and following institutional radiation safety guidelines,
the calculated activity of 90Y-microspheres was administered selectively to the target hepatic
lobe by intra-arterial infusion at low pressure (20–40 pounds per square inch), according to the
manufacturer's instructions. Treatment was delivered on an outpatient basis, where patients
were observed in recovery for 4 to 6 hours and were discharged to home when they were
clinically stable and without complaints.
Patients with bilobar disease that received glass microspheres were scheduled for treatment of
the opposite lobe 30–60 days after initial treatment, according to the original treatment plan.
Patients treated with resin microspheres who required retreatment were treated at least 90 days
from the first treatment.
To determine eligibility for re-treatment, patients had a repeat treatment work-up, as performed
before initial treatment. At the time of re-treatment evaluation, consideration of the total dose
to the lungs was based on the cumulative dose of all treatments and could not exceed an
estimated cumulative dose of 50 Gy as calculated by the calculated dose to the lung from the
first treatment and the estimated lung shunt fraction from the repeat 99mTc-MAA scan (20–
21). In patients with complex tumor presentations who required more than two treatments to
achieve tumor coverage, or in patients being retreated after progression, the safety re-evaluation
was repeated before each treatment and the calculation of cumulative lung dose included all
previous treatments.
Data Collection
Data comprised information on demographics, tumor characteristics and outcomes. Baseline
evaluations taken prior to therapy were used to calculate Child-Pugh and Cancer of the Liver
Italian Program (CLIP) scores (22). Liver function tests were collected prior to therapy and 7
to 30 days after therapy. Outcomes data after treatment included treatment-related adverse
events (AEs), imaging response and overall survival. All adverse events were classified and
coded for severity using the Common Terminology Criteria for Adverse Events (CTCAE)
version 3.0. Response was determined approximately 8–12 weeks following treatment using
MR (whenever possible) or CT scans and evaluated using the new international criteria
proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee (23).
Patients were classified as positive for intra-hepatic disease progression based on comparative
evaluation of pre- and post-treatment CT or MR images. All measurable (non-infiltrative)
tumor lesions per patient were documented; however, only changes in the largest diameter
(uni-dimensional measurement) tumor lesion was used to determine response, per RECIST
criteria. Patients were considered to have intra-hepatic disease progression if there was visual
evidence of increasing lesion size or new lesion development.
Statistical Methods
The Kaplan-Meier (or product limit) method was used to estimate survival curves. Overall
survival (OS) has been defined as the time from the date of the start of treatment to the date of
death (event) or the date of last contact (censored). The log-rank test was used to test for
significant differences between estimated the survival curves. Exact 95% confidence intervals
were calculated for each proportion of interest (and reported as percentages). Statistical
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analyses were performed with SAS statistical software, version 9.2, SAS Institute Inc., Cary,
NC.
RESULTS
Thirty-two treatments (26 glass, 6 resin spheres) were administered to 22 patients. Rates of
PVT by branch were 5/22, 7/22, and 10/22 (or 23%, 32% and 45%) for left, right and main
branches of the portal vein respectively. The median age of the entire cohort was 57.5 years
(range, 18–78). The majority of patients were male (20 or 91%) and Caucasian (18 or 82%),
with a small number of Asians (2 or 9%) and African-Americans (2 or 9%). For patients treated
with resin 90Y-microspheres, all patients received their planned radiation doses with resulting
near but not complete angiographic stasis and pulsatile forward flow documented at the end
of each case.
Patient baseline characteristics are presented in Table 1. The average tumor burden at baseline
for the entire patient cohort was significant, with 4 (18%) of patients having ≥50% liver
replacement by tumor, 12 (55%) with bi-lobar disease and 3 (14%) with extra-hepatic disease.
Patients had varying degrees of liver dysfunction, with 7 (32%) having grade 1 or higher ascites
and 9 (41%) with total bilirubin levels >1.2 mg/dL. These factors are reflected in Child-Pugh
and CLIP score distributions of the study population. Patients generally had mild to moderate
degrees of cirrhosis with 12, 6, and 1 (or 55%, 27% and 5%) having Child-Pugh scores of A,
B and C respectively. CLIP scores ranged from 2–5 with 18% having a CLIP score of 4 or
greater. Patients with unifocal (3 or 14%), multifocal (12 or 55%), or infiltrative (7 or 32%)
disease were all included in the study. Three patients (14%) were treated who had initial
bilirubin levels outside of recommended values. Their bilirubin levels were 2.3, 2.5, and 7.3
mg/dL, and all three were treated with glass spheres. The patient with the highest bilirubin had
a steep increase in bilirubin prior to treatment, had no other treatment options, and insisted on
therapy in spite of warnings of potential toxicity.
All patients received the planned 90Y-microspheres dose at each treatment without technical
complications. Fifteen (68%) patients received only a single 90Y-microspheres treatment. Four
patients underwent a total of 2 treatments and three patients underwent a total of 3 treatments.
The indication for re-treatment was progressive disease. Patients with multilobar disease
receiving multiple treatments all received sequential lobar treatments except for 2 cases in
which whole liver treatment was done. The median interval between treatments was 98 days.
The mean dose administered was 2.7 GBq, and doses ranged from 0.59 to 9.21 GBq.
The incidence of short-term (within 30 days) complications following treatment in this patient
population was moderate. Table 2 lists minor and major adverse events in the 22 patients treated
according to (CTCAE) version 3.0 reporting standards. The most common grade 1–2 toxicities
include abdominal pain (n=12, 38%), nausea (n=9, 28%), fatigue (n=7, 22%) and anorexia
(n=6, 19%). The most common grade 3–4 toxicities include ascites (n=4, 13%), encephalopathy
(n=4, 13%), fatigue (n=3, 9%) and abdominal pain (n=3, 9%). There were 4 post-treatment
hospitalizations all lasting <48 hours. Three were for signs related to liver failure
(encephalopathy and/or large volume ascites), one was due to worsening abdominal pain. One
death occurred 10 days following treatment, secondary to liver failure in a patient with bilirubin
outside entry criterion (7.3 mg/dL). Of the 32 treatments, no adverse event of any type was
reported in 25% of treatments.
Common laboratory adverse events included increases in total bilirubin, AST and ALT levels.
Total bilirubin was elevated to grade 1–2 levels following 6 (19%) of the treatments and to
grade 3–4 levels following 4 (13%) of the treatments. AST was elevated to grade 1–2 levels
following 13 (41%) of the treatments and to grade 3–4 levels following 4 (13%) of the
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treatments. ALT was elevated to grade 1–2 levels following 9 (28%) of the treatments; no grade
3–4 elevations occurred. Of the 28 instances of grade 1–2 LFT elevation, 15 (53%) returned
to within normal limits or baseline. Of the 8 instances of grade 3–4 LFT elevation, 1 (13%)
returned to within normal limits or baseline. It should be noted that all patients experiencing
grade 3–4 elevations in LFTs had pre-treatment LFTs already above the upper limits of normal.
Of the 32 treatments administered, response could be evaluated for the treated lobe in 24
treatments (15 patients). Unevaluated treatments were due to diffuse (unmeasurable) disease
(found in 4 patients) or due to lack of follow up scanning (following 4 treatments, 3 secondary
to patient death). Of the 24 instances of measurable disease in the treated lobe, 2 partial
responses (or 8%; 95% CI: 1%–27%) were noted, 12 (or 50%; 95% CI: 29%–71%) resulted
in stable disease, and 10 (or 42%; 95% CI: 22%–63%) resulted in progressive disease. For
details, see Table 3.
Of the twenty-two patients included in the analysis, thirteen have died, and nine were still alive
at last follow up (see Figure 1 for a Kaplan-Meier OS plot of this cohort.) Median follow-up
for survivors was approximately nine months. Five patients were alive greater than 9 months
out from first treatment, and one patient was alive more than 30 months from the date of first
treatment. Median overall survival was 7 months. The primary analysis cohort included three
patients with bilirubin levels over 2 mg/dL at the time of therapy. When these patients were
excluded from analysis, median OS increased to 8 months. When the patient with the longest
survival was excluded from analysis, median OS decreased to 5 months. Patients with Child-
Pugh A liver disease had a significantly longer median OS of 7.7 months, versus those with
Child-Pugh B and C liver disease whose median OS was 2.7 months (p = 0.01, Figure 2).
Similarly, patients with CLIP scores of 2–3 had a median OS of 7 months compared with 1.3
months for patients with CLIP scores of 4–5 (p = 0.04, Figure 3). There was no significant
difference in survival between patients with main vs. branch PVT (OS 4.4 and 7 months
respectively, p = 0.36).
DISCUSSION
The prognosis for patients with advanced HCC complicated by PVT is poor; it has been
reported that these patients have a median survival of only 2.7 to 4 months when untreated
(3–5). Many treatment modalities exist for patients with HCC and PVT, however treatment
benefit remains difficult to ascertain and an optimal treatment strategy has yet to emerge. PVT
precludes a patient from transplantation due to the high incidence of tumor recurrence. The
longest median survival times in HCC with PVT have been reported in patients able to undergo
surgical resection, with studies showing median survival times of 9 to 22 months (24).
Unfortunately, most patients (e.g., those with main or first branch PVT, diffuse disease, or
cirrhotic change) are ineligible for surgery. Systemic therapies including chemotherapy,
hormonal therapy, and interferon have shown limited benefit in this patient population (25).
Recent results with sorafenib, an oral multikinase inhibitor, show promise and may represent
a new standard for comparison (26). At this point, however, the survival of the subgroup of
patients with significant PVT treated with sorafenib has not been reported; rather this group
has been included with patients with metastatic disease. Embolic therapies such as
chemoembolization or transarterial embolization, which are the mainstay for treating
unresectable HCC, may be a relative contraindication in this patient population due to their
limited hepatic reserve. In one publication, use of limited embolization with lipiodol and
chemotherapy was tolerable, and resulted in a promising survival of 9 months (27). The patient
population in this study, however, was comprised of a larger fraction of Child-Pugh A patients
compared with our study. A recent study of 59 patients receiving three-dimensional conformal
radiotherapy for PVT of HCC showed a 45.8% response rate with a median survival of 10.7
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months in the responders. However, median survival for the non-responders, which comprised
54.2% of the population, was 5.3 months (28).
In contrast to chemoembolization or transarterial embolization, therapy with 90Y-
microspheres exerts less of an ischemic effect. Although embolization with 90Y-microspheres
does result in permanent vascular blockade with glass or resin particles, the smaller caliber of
the particles (20–30μm glass, 20–60μm resin) impart the theoretical advantage of a lesser
degree of macroscopic arterial occlusion. Accordingly, studies have reported a three fold lower
incidence of post-embolization syndrome (abdominal pain, fever, and nausea/vomiting)
following 90Y-microsphere therapy compared to chemoembolization (29). Our study shows
a 38% incidence of mild abdominal pain, a 28% incidence of mild nausea and 13% incidence
of mild vomiting following 90Y-microsphere treatments. There was only a 9% incidence of
severe abdominal pain following treatments, and no incidents of severe nausea/vomiting. This
is comparable to the reported post-embolization syndrome incidences of 18% following glass
90Y-microsphere administration for HCC (29) and 25% following resin 90Y-microspheres for
hepatic metastases (30). This is less than the 50% incidence of post-embolization syndrome
reported following chemoembolization in HCC with PVT (27). There were 4 hospitalizations
(≤48 hours) following therapy, 3 for complications related to liver failure and 1 due to
increasing abdominal pain. Two out of 4 of these hospitalizations occurred in patients with
bilirubin levels outside of entry criterion. Similarly, the one death that occurred following
treatment was in a patient with bilirubin levels elevated to 7.3 prior to therapy. Median survival
for our patient population was approximately 7 months (95% CI: 4–18 months). This is
comparable to other studies of 90Y-microsphere use where median survivals of 10.0, 4.4 and
3.2 months were reported for HCC patients with branch, main and mixed (IVC, main and/or
branch) PVT, respectively (13,31). Our results also fell in the same range when compared to
other local non-embolic therapies such as hepatic arterial infusion chemotherapy. In a study
by Takizawa, et al. examining continuous hepatic arterial infusion chemotherapy in these
patients, median survival was 8.0 months (25). In a similar study of hepatic arterial infusion
chemotherapy by Ikeda et al., median survival was 6.0 months (32). For details see Table 4.
Using prognostic factors as defined by the CLIP system as a basis for comparison with a
historical control group, we find that the survival of our patients tended to be less than predicted.
Expected median survivals for patients with CLIP scores of 2 or 3 are 13 and 7 to 8 months
respectively; expected median survival for patients with CLIP scores of 4 or 5 is 2 to 3.2 months
(33–34). However, it is known that PVT is an independent predictor of poor prognosis and can
contribute to prognostic variability even within the same CLIP score. For example, a recent
study examined intra-score variations within the CLIP system and found that median survival
for patients with CLIP scores of 2 and 3 and PVT ranged from 3.5 to 6.6 months and 1.7 to 6.1
months respectively, compared to patients without PVT (6.7 to 17.9 months and 3.7 to 7.3
months respectively) (35). A similar trend is true for patients with CLIP scores of 4 and 5.
Based on that report, it does not appear as if our patients tended to fare any better or worse
than predicted, based on their CLIP score. For details see Table 5.
Based on these comparisons, it is not obvious that therapy with 90Y-microspheres in patients
with HCC and PVT offers a survival benefit when compared with historical controls. This
would particularly apply to patients with Child-Pugh B liver disease or CLIP scores of 4 or
greater who had very short survival after treatment in our series. This conclusion is of course
limited by the fairly wide range of reported outcomes for this patient population, and none of
the current prognostic scores seems to appropriately narrow the range of survivals for this
group. One potential confounding factor is that our study included patients with extra-hepatic
disease, which are frequently excluded from other studies (notably, the similar 90Y-
microsphere study by Salem et al., 12, the hepatic arterial infusion chemotherapy study by
Ikeda et al., 32, and the chemoembolization study by Georgiades et al., 27.) Additional
Tsai et al. Page 7













limitations include the retrospective nature of this and many other studies, the analysis of only
acute toxicities as opposed to longer term toxicities as might occur with radiation-induced liver
disease, as well as the heterogeneity of HCC patients even among the subset of those with PVT.
In conclusion, 90Y-microspheres may prolong survival beyond the median of 2.7 months
reported for untreated HCC with PVT. Compared with chemoembolization, rates of severe
adverse events appear low. As in other series, the one death in our series occurred in a patient
with elevated bilirubin pre-treatment. Further comparison between 90Y-microspheres and
systemic therapies is warranted given recent sorafenib data in an overlapping patient
population.
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Overall survival curve of 22 patients with HCC and PVT treated with 90Y-microspheres.
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Survival curve for Child-Pugh A (solid line) vs. B and C (dashed line) patients.
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Survival curve for CLIP score 2–3 (solid line) vs. 4–5 (dashed line) patients.
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Table 1
Patient characteristics prior to 90Y-microsphere treatment
Characteristic Statistic
Age (years)
Median (range) 57.5 (18–78)








Grade 0 15 (68%)
Grade 1–2 5 (23%)
Grade 3–4 2 (9%)
Serum Total Bilirubin (mg/dL)
Median (range) 0.85 (0.1–7.3)
>1.2 mg/dL, n (%) 9 (41%)
Tumor Distribution, n (%)
Unilobar 10 (45%)
Bilobar 12 (55%)
Tumor Morphology, n (%)
Uninodular, <50% Replacement 3 (14%)
Multinodular, <50% Replacement 15 (68%)
Massive, ≥50% Replacement 4 (18%)




Unable To Be Determined 3 (14%)








Unable To Be Determined 5 (23%)








































































































































































































































































































































































































































































































































































































































































































































































































n (%) 95% CI*
Complete Response 0 (0%) 0%–14%
Partial Response 2 (8%) l%–27%
Stable Disease 12 (50%) 29%–71%
Progressive Disease 10 (42%) 22%–63%
Total 24 (100) N/A
Unmeasurable 4 (N/A) N/A
N/A 4 (N/A) N/A
*
CI: exact confidence interval
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Table 4
Non-embolic trans-arterial therapies for HCC - median survival in patients with PVT.
Treatment PVT Type N Median (months) 95% CI* (months)
90Y-microspheres (31) IVC/main/1st 15 3.2
90Y-microspheres (13) Main 12 4.4 3–7
Hepatic arterial infusion chemotherapy (32) Main/1st 45 6
90Y-microspheres (current study) Main/1st 22 7 4–18
Continuous hepatic arterial infusion chemotherapy (25) Main/branch 52 8
90Y-microspheres (13) Branch (1st) 25 10 7–16
*
CI: confidence interval
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